Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02788513 · ClinicalTrials.gov registry record · Phase 2

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

A Phase 2 study of Alzheimer Disease, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 2
Development phase
611
Enrollment target
20
Study locations

NCT02788513 is a Phase 2 study of Alzheimer Disease that has completed, run by Boehringer Ingelheim. The registered enrollment target is 611 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02788513, a Phase 2 study of Alzheimer Disease, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 2
Development phase
611 participants
Enrollment target
20
Study locations

Study Summary

The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG Placebo
  • DRUG BI 425809 dose 1
  • DRUG BI 425809 dose 2
  • DRUG BI 425809 dose 3
  • DRUG BI 425809 dose 4

Study Locations (20)

Florida

  • MD Clinical - Hallandale
  • Galiz Research - Miami
  • Premier Clinical Research Institute - Miami
  • Miami Jewish Health System - Miami
  • Stedman Clinical Trials - Tampa
  • Bioclinica Research - The Villages

California

  • Axiom Research LLC - Colton
  • Alliance for Wellness - Long Beach
  • Anderson Clinical Research - Redlands
  • CITrials - Santa Ana

Other

  • LKH-Univ. Hospital Graz - Graz
  • Medical University of Innsbruck - Innsbruck
  • SALK Christian-Doppler-Klinik,Paracel.Med.Privatuni.f.Neurol - Salzburg

Georgia

  • Neuro Trials Research Incorporated - Atlanta

Missouri

  • Millennium Psychiatric Associates LLC - St Louis

North Carolina

  • ANI Neurology, PLLC, dba Alzheimer's Memory Center - Charlotte

Oklahoma

  • Tulsa Clinical Research, LLC - Tulsa

Pennsylvania

  • Northeastern Pennsylvania Memory and Alzheimer Center - Plains

Trial Details

FieldValue
Enrollment Target 611 participants
Start Date 2016-08-11
Est. Completion 2019-10-11
Phase Phase 2

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02788513

The ClinicalTrials.gov registry entry for NCT02788513 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 611 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (78% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT02788513 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Other.

Frequently Asked Questions

What is clinical trial NCT02788513 about?

NCT02788513 is a clinical study titled "BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.". The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.

What is the current status of trial NCT02788513?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 611 participants. The study started on 2016-08-11. Estimated completion is 2019-10-11.

What conditions does trial NCT02788513 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT02788513?

The interventions under investigation include: Placebo (DRUG), BI 425809 dose 1 (DRUG), BI 425809 dose 2 (DRUG), BI 425809 dose 3 (DRUG), BI 425809 dose 4 (DRUG).

Who is sponsoring clinical trial NCT02788513?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02788513 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.